** Shares of drugmaker Eyenovia EYEN.O rise 6.1% to 11 cents premarket
** EYEN says it will take additional actions to reduce ongoing personnel-related costs by more than 70%
** Co adds investment firm Avenue Capital has agreed to restructure loan agreement and delay EYEN's debt repayments, including principal and interest, until February 2025
** As of Nov. 19, EYEN owed $10.1 million in principal and accrued interest under the agreement with Avenue Capital, according to a regulatory filing earlier this week
** EYEN had 57 full-time employees as of March 15, according to its latest annual report
** Co has been evaluating alternatives after its experimental drug-device combination for an eye disease failed in a late-stage study earlier this month
** As of last close, stock had fallen ~95% YTD
(Reporting by Kamal Choudhury in Bangalore)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。